patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_509145 | REC_0005801 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.5 | 55 | female | 0 | 11 | 6.3 | 4 | sotorasib 960 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:35:58.279606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315346 | REC_0005802 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 10.7 | 60 | male | 0 | 16 | 4 | 1 | osimertinib 80 mg daily | 21.7 | true | MSI-H | 2026-03-15T05:35:58.279844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917095 | REC_0005803 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.4 | 70 | female | 2 | 18 | 5.4 | 5 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:58.280116+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_251012 | REC_0005804 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 13 | 21.8 | 71 | female | 1 | 21 | 5.9 | 5 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.280369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698968 | REC_0005805 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7 | 66 | male | 1 | 39 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:35:58.280605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911914 | REC_0005806 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 13 | 12.2 | 57 | male | 0 | 11 | 3.2 | 5 | pembrolizumab 200 mg q3w | 9.3 | true | MSI-H | 2026-03-15T05:35:58.280840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584102 | REC_0005807 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 32 | 15.3 | 77 | male | 2 | 13 | 4.5 | 0 | alectinib 600 mg BID | 22.7 | false | MSI-H | 2026-03-15T05:35:58.281076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353420 | REC_0005808 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 10.5 | 62 | female | 1 | 23 | 7.2 | 1 | sotorasib 960 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:58.281313+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314297 | REC_0005809 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 14.3 | 60 | male | 1 | 8 | 6 | 6 | osimertinib 80 mg daily | 16 | false | MSI-H | 2026-03-15T05:35:58.281547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751797 | REC_0005810 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 6.8 | 78 | male | 0 | 11 | 6.5 | 2 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:58.281778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124373 | REC_0005811 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.4 | 60 | female | 0 | 16 | 5.1 | 7 | pembrolizumab 200 mg q3w | 7.8 | true | MSS | 2026-03-15T05:35:58.282008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498319 | REC_0005812 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 7 | 76 | female | 1 | 9 | 3.8 | 7 | alectinib 600 mg BID | 15.4 | true | MSS | 2026-03-15T05:35:58.282280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317653 | REC_0005813 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 13.8 | 85 | female | 2 | 18 | 5.1 | 2 | osimertinib 80 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:35:58.282518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533118 | REC_0005814 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.1 | 66 | female | 1 | 59 | 6.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:58.282747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332733 | REC_0005815 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 13.8 | 64 | female | 1 | 21 | 3.5 | 0 | osimertinib 80 mg daily | 38 | false | MSI-H | 2026-03-15T05:35:58.282985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859463 | REC_0005816 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 15.3 | 60 | male | 0 | 19 | 5 | 2 | alectinib 600 mg BID | 22.1 | false | MSI-H | 2026-03-15T05:35:58.283218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133960 | REC_0005817 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 14.3 | 72 | female | 2 | 16 | 5.8 | 1 | alectinib 600 mg BID | 20 | true | MSS | 2026-03-15T05:35:58.283450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611616 | REC_0005818 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 10.5 | 74 | male | 3 | 4 | 6.2 | 7 | sotorasib 960 mg daily | 4.3 | true | MSI-H | 2026-03-15T05:35:58.283682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441116 | REC_0005819 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.7 | 67 | female | 0 | 11 | 7.4 | 2 | alectinib 600 mg BID | 12.1 | false | MSS | 2026-03-15T05:35:58.283913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690694 | REC_0005820 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 14.6 | 69 | male | 0 | 9 | 6.5 | 7 | alectinib 600 mg BID | 9.3 | false | MSI-H | 2026-03-15T05:35:58.284176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125312 | REC_0005821 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 10.7 | 75 | male | 1 | 18 | 4.4 | 7 | alectinib 600 mg BID | 10.3 | true | MSS | 2026-03-15T05:35:58.284416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859117 | REC_0005822 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 10.1 | 70 | female | 2 | 17 | 6.7 | 0 | osimertinib 80 mg daily | 51.7 | false | MSS | 2026-03-15T05:35:58.284654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356279 | REC_0005823 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 19 | 11.5 | 74 | female | 2 | 6 | 4.1 | 1 | pembrolizumab 200 mg q3w | 10.9 | true | MSI-H | 2026-03-15T05:35:58.284886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992549 | REC_0005824 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 4.9 | 59 | male | 0 | 16 | 3.8 | 1 | sotorasib 960 mg daily | 19.5 | true | MSS | 2026-03-15T05:35:58.285116+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169847 | REC_0005825 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 12.8 | 67 | female | 1 | 19 | 7.8 | 4 | pembrolizumab 200 mg q3w | 9.1 | false | MSS | 2026-03-15T05:35:58.285393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317248 | REC_0005826 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 9.9 | 54 | male | 0 | 25 | 4.6 | 6 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:58.285672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303877 | REC_0005827 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 13.3 | 64 | female | 0 | 22 | 4.8 | 2 | osimertinib 80 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:58.285911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940129 | REC_0005828 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 14.2 | 71 | male | 1 | 13 | 5.2 | 4 | osimertinib 80 mg daily | 7.3 | false | MSS | 2026-03-15T05:35:58.286147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186858 | REC_0005829 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 10.2 | 67 | female | 0 | 6 | 6.6 | 2 | alectinib 600 mg BID | 15.7 | false | MSI-H | 2026-03-15T05:35:58.286379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205088 | REC_0005830 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 13.4 | 64 | male | 1 | 17 | 4.1 | 2 | osimertinib 80 mg daily | 16.7 | true | MSS | 2026-03-15T05:35:58.286612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827407 | REC_0005831 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 3.5 | 76 | female | 2 | 4 | 6.2 | 2 | alectinib 600 mg BID | 9 | false | MSS | 2026-03-15T05:35:58.286842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363209 | REC_0005832 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 6.1 | 65 | female | 1 | 51 | 4.3 | 6 | pembrolizumab 200 mg q3w | 4.5 | false | MSS | 2026-03-15T05:35:58.287072+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534427 | REC_0005833 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 17 | 6.6 | 70 | female | 2 | 21 | 3.7 | 1 | pembrolizumab 200 mg q3w | 21 | true | MSS | 2026-03-15T05:35:58.287309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376151 | REC_0005834 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.4 | 64 | male | 0 | 87 | 7.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.7 | true | MSS | 2026-03-15T05:35:58.287541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122283 | REC_0005835 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 6.2 | 64 | female | 1 | 9 | 6.3 | 2 | pembrolizumab 200 mg q3w | 23.2 | true | MSS | 2026-03-15T05:35:58.287811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500755 | REC_0005836 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 10.8 | 63 | female | 0 | 6 | 6 | 1 | alectinib 600 mg BID | 20.9 | false | MSI-H | 2026-03-15T05:35:58.288050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762879 | REC_0005837 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 6.4 | 65 | female | 0 | 6 | 4 | 6 | sotorasib 960 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:58.288309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794559 | REC_0005838 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 4.7 | 54 | male | 0 | 9 | 7.7 | 5 | osimertinib 80 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:58.288626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619864 | REC_0005839 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 21 | 11.4 | 60 | male | 0 | 23 | 6.9 | 0 | osimertinib 80 mg daily | 27 | false | MSS | 2026-03-15T05:35:58.288867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592915 | REC_0005840 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11 | 64 | male | 0 | 13 | 5.5 | 4 | alectinib 600 mg BID | 8.4 | true | MSS | 2026-03-15T05:35:58.289146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579826 | REC_0005841 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 8.1 | 60 | male | 1 | 7 | 3.9 | 0 | osimertinib 80 mg daily | 25.3 | true | MSS | 2026-03-15T05:35:58.289382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941136 | REC_0005842 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 10.8 | 75 | male | 2 | 16 | 6.3 | 1 | osimertinib 80 mg daily | 19.3 | false | MSS | 2026-03-15T05:35:58.289638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723710 | REC_0005843 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 17 | 10.3 | 70 | female | 2 | 17 | 5.5 | 4 | pembrolizumab 200 mg q3w | 7.1 | false | MSS | 2026-03-15T05:35:58.290055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484851 | REC_0005844 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.7 | 64 | male | 0 | 8 | 4.3 | 1 | entrectinib 600 mg daily | 21.3 | false | MSI-H | 2026-03-15T05:35:58.290464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243989 | REC_0005845 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11 | 60 | female | 1 | 18 | 5 | 5 | entrectinib 600 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:58.290777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455272 | REC_0005846 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 14.5 | 52 | female | 0 | 1 | 6.2 | 1 | entrectinib 600 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:35:58.291016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445846 | REC_0005847 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12.8 | 75 | female | 2 | 23 | 6 | 7 | alectinib 600 mg BID | 11.9 | false | MSI-H | 2026-03-15T05:35:58.291251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762488 | REC_0005848 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.1 | 58 | female | 0 | 40 | 4.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.1 | false | MSS | 2026-03-15T05:35:58.291481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194456 | REC_0005849 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 35 | 9.8 | 83 | female | 2 | 19 | 6.7 | 5 | sotorasib 960 mg daily | 16.5 | true | MSS | 2026-03-15T05:35:58.291715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210122 | REC_0005850 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 32 | 3.6 | 77 | female | 1 | 44 | 6 | 0 | carboplatin + paclitaxel + pembrolizumab | 29.6 | false | MSS | 2026-03-15T05:35:58.291946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222244 | REC_0005851 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 6.5 | 64 | male | 0 | 27 | 5.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:58.292280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454887 | REC_0005852 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.7 | 68 | female | 0 | 38 | 3.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.3 | false | MSS | 2026-03-15T05:35:58.292512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437737 | REC_0005853 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 10.1 | 72 | female | 2 | 9 | 5.6 | 6 | osimertinib 80 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:58.292762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537978 | REC_0005854 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 12.3 | 64 | female | 1 | 5 | 5.5 | 3 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:58.292999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250092 | REC_0005855 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 11.9 | 71 | female | 2 | 9 | 4.3 | 3 | osimertinib 80 mg daily | 4.4 | true | MSI-H | 2026-03-15T05:35:58.293231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234082 | REC_0005856 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.3 | 71 | male | 2 | 13 | 3.4 | 7 | osimertinib 80 mg daily | 8.8 | true | MSI-H | 2026-03-15T05:35:58.293464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118905 | REC_0005857 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 13.1 | 67 | female | 0 | 20 | 6.3 | 5 | osimertinib 80 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:35:58.293697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309592 | REC_0005858 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14.2 | 67 | female | 1 | 23 | 5.9 | 2 | entrectinib 600 mg daily | 19.9 | true | MSS | 2026-03-15T05:35:58.293931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602587 | REC_0005859 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.2 | 64 | female | 1 | 32 | 6.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 5.1 | false | MSS | 2026-03-15T05:35:58.294164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514842 | REC_0005860 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 9.7 | 74 | female | 1 | 19 | 6.4 | 5 | entrectinib 600 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:58.294390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795406 | REC_0005861 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 16.5 | 86 | female | 1 | 16 | 6.9 | 5 | sotorasib 960 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:58.294619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559479 | REC_0005862 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 13.2 | 77 | male | 2 | 12 | 4.5 | 5 | sotorasib 960 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:58.294854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283440 | REC_0005863 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 15.7 | 63 | male | 1 | 15 | 5.5 | 5 | osimertinib 80 mg daily | 7.2 | true | MSI-H | 2026-03-15T05:35:58.295092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334514 | REC_0005864 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 14.3 | 79 | female | 3 | 15 | 4.4 | 1 | alectinib 600 mg BID | 25.6 | false | MSI-H | 2026-03-15T05:35:58.295367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849211 | REC_0005865 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 10.8 | 71 | female | 2 | 2 | 5.8 | 2 | osimertinib 80 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:35:58.295607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247917 | REC_0005866 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.7 | 77 | female | 2 | 22 | 5.2 | 3 | alectinib 600 mg BID | 8.4 | false | MSI-H | 2026-03-15T05:35:58.295837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996526 | REC_0005867 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 14.9 | 62 | female | 1 | 11 | 5.6 | 4 | osimertinib 80 mg daily | 17.1 | true | MSS | 2026-03-15T05:35:58.296208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521222 | REC_0005868 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 37 | 15.1 | 65 | female | 0 | 22 | 5.2 | 5 | sotorasib 960 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:35:58.296457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647772 | REC_0005869 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.2 | 73 | male | 1 | 9 | 5.3 | 7 | osimertinib 80 mg daily | 13.3 | true | MSI-H | 2026-03-15T05:35:58.296698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304242 | REC_0005870 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 5.4 | 73 | female | 1 | 41 | 3.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.9 | true | MSS | 2026-03-15T05:35:58.296930+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114143 | REC_0005871 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 5.1 | 73 | female | 3 | 18 | 6 | 4 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:35:58.297166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356894 | REC_0005872 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 11 | 58 | male | 1 | 20 | 5.9 | 9 | osimertinib 80 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:58.297400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671763 | REC_0005873 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 9.9 | 59 | female | 0 | 49 | 7.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.6 | false | MSS | 2026-03-15T05:35:58.297633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663042 | REC_0005874 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8 | 76 | female | 1 | 28 | 7.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 15.5 | true | MSS | 2026-03-15T05:35:58.297860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444529 | REC_0005875 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.4 | 59 | male | 1 | 6 | 6.8 | 4 | osimertinib 80 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:58.298096+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196011 | REC_0005876 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 11.6 | 54 | female | 0 | 12 | 4.6 | 2 | entrectinib 600 mg daily | 17.7 | true | MSS | 2026-03-15T05:35:58.298330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313674 | REC_0005877 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14.9 | 52 | male | 0 | 18 | 4.2 | 1 | entrectinib 600 mg daily | 21.9 | false | MSI-H | 2026-03-15T05:35:58.298611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722366 | REC_0005878 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.4 | 49 | male | 0 | 18 | 4.7 | 6 | alectinib 600 mg BID | 10.2 | true | MSI-H | 2026-03-15T05:35:58.298849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716147 | REC_0005879 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 16.7 | 66 | female | 1 | 22 | 3.6 | 4 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:58.299085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459368 | REC_0005880 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 15.2 | 80 | male | 1 | 8 | 6.2 | 0 | sotorasib 960 mg daily | 19.7 | true | MSI-H | 2026-03-15T05:35:58.299321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916968 | REC_0005881 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 12.4 | 60 | male | 1 | 9 | 4.6 | 1 | alectinib 600 mg BID | 6.6 | true | MSI-H | 2026-03-15T05:35:58.299556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_479645 | REC_0005882 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 15 | 11.2 | 77 | female | 2 | 11 | 5.7 | 2 | sotorasib 960 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.299791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437308 | REC_0005883 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 13.3 | 74 | female | 1 | 15 | 5.4 | 1 | sotorasib 960 mg daily | 15.8 | false | MSI-H | 2026-03-15T05:35:58.300024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798138 | REC_0005884 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 14.1 | 69 | male | 1 | 4 | 2.6 | 2 | osimertinib 80 mg daily | 5.1 | true | MSI-H | 2026-03-15T05:35:58.300289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395446 | REC_0005885 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 6.4 | 64 | male | 0 | 22 | 6.9 | 6 | pembrolizumab 200 mg q3w | 14 | false | MSS | 2026-03-15T05:35:58.300523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232393 | REC_0005886 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 9.6 | 83 | male | 2 | 27 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:35:58.300755+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625373 | REC_0005887 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.7 | 66 | female | 1 | 6 | 8.5 | 5 | alectinib 600 mg BID | 4.2 | true | MSS | 2026-03-15T05:35:58.300988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288632 | REC_0005888 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.7 | 61 | female | 0 | 40 | 4.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:35:58.301218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239341 | REC_0005889 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 14.4 | 74 | female | 2 | 14 | 6.8 | 2 | osimertinib 80 mg daily | 7.5 | false | MSI-H | 2026-03-15T05:35:58.301449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533504 | REC_0005890 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.2 | 60 | male | 0 | 41 | 3.6 | 5 | pembrolizumab 200 mg q3w | 11.6 | false | MSS | 2026-03-15T05:35:58.301727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373922 | REC_0005891 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 3.7 | 59 | female | 0 | 14 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 19 | false | MSS | 2026-03-15T05:35:58.301964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497005 | REC_0005892 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 7 | 69 | female | 1 | 11 | 4.5 | 2 | sotorasib 960 mg daily | 22.4 | false | MSS | 2026-03-15T05:35:58.302194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408898 | REC_0005893 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 8.6 | 66 | female | 1 | 15 | 4.9 | 2 | osimertinib 80 mg daily | 22.9 | false | MSS | 2026-03-15T05:35:58.302422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499216 | REC_0005894 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 15 | 57 | female | 1 | 16 | 5.1 | 5 | pembrolizumab 200 mg q3w | 13.6 | false | MSS | 2026-03-15T05:35:58.302659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945344 | REC_0005895 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.3 | 79 | female | 1 | 45 | 3.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.5 | true | MSS | 2026-03-15T05:35:58.302886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677702 | REC_0005896 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 15.3 | 66 | male | 1 | 19 | 5.5 | 1 | alectinib 600 mg BID | 14.9 | false | MSI-H | 2026-03-15T05:35:58.303121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908670 | REC_0005897 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 33 | 15.9 | 70 | female | 3 | 18 | 7.3 | 6 | pembrolizumab 200 mg q3w | 14.3 | true | MSI-H | 2026-03-15T05:35:58.303355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139216 | REC_0005898 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13.5 | 86 | female | 2 | 10 | 3.5 | 8 | osimertinib 80 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:58.303588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165166 | REC_0005899 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 3.6 | 71 | female | 1 | 77 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.3 | true | MSS | 2026-03-15T05:35:58.303819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222258 | REC_0005900 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.5 | 68 | male | 1 | 16 | 5 | 6 | entrectinib 600 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:58.304053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.